Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamEMab Dose Escalation in Healthy Volunteers
NCT03428347Phase 1Completed
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GamEMab in Ebola virus disease (EVD) (3 arms). Primary endpoint: Number of Participants With Adverse Events at 90 days. Started Mar 2018; status: completed.
02
Drugs
GamEMab
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT03428347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428347.